Research progress on the role of TLR2 in the development of gastrointestinal cancer

doi:10.16352/j.issn.1001-6325.2023.08.1304

Abstract

Abstract: Toll-like receptor 2 (TLR2) is a pattern recognition receptor (PRR) that mediates immune and inflammatory responses, angiogenesis, and other physiological processes using the TLR2-MyD88 pathway. It is expressed on the cell surface, activated by exogenous PAMPs and endogenous DAMPs, and mediates the development of gastrointestinal cancer by regulating nuclear RNA expression through classical and non-classical signaling pathways such as MyD88, PI3K/Akt, Wnt/β-catenin, and MAPK.

Key words: TLR2, cancer, gastrointestinal cancer

CLC Number:

R392.12

ZOU Yuxiang, TANG Hui. Research progress on the role of TLR2 in the development of gastrointestinal cancer[J]. Basic & Clinical Medicine, 2023, 43(8): 1304-1308.

References 27

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2:1-9.
[2]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71:209-249.
[3]	Scheeren FA, Kuo AH, van Weele LJ, et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis[J]. Nat Cell Biol, 2014, 16:1238-1248.
[4]	Martínez A, Bono C, Gozalbo D, et al. TLR2 and dectin-1 signaling in mouse hematopoietic stem and progenitor cells impacts the ability of the antigen presenting cells they produce to activate CD4 T cells[J]. Cells, 2020, 9:1317.doi:10.3390/cells9051317.
[5]	Su YR, Chen MT, Xiong K, et al. Endogenous Toll-like receptor 2 modulates Th1/Treg-promoting dendritic cells in mice corneal transplantation model[J]. Curr Eye Res, 2020, 45:774-781.
[6]	Nakao M, Sugaya M, Fujita H, et al. TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T cells and impaired IL-10 production[J]. Int J Mol Sci, 2020, 21:8560.doi:10.3390/ijms21228560.
[7]	Im J, Baik JE, Lee D, et al. Bacterial lipoproteins induce BAFF production via TLR2/MyD88/JNK signaling pathways in dendritic cells[J]. Front Immunol, 2020, 11:564699.doi:10.3389/fimmu.2020.564699.
[8]	Mccoy MG, Nascimento DW, Veleeparambil M, et al. Endothelial TLR2 promotes proangiogenic immune cell recruitment and tumor angiogenesis[J]. Sci Signal, 2021, 14:eabc5371.doi:10.1126/scisignal.abc5371.
[9]	Lundy J, Gearing LJ, Gao H, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma[J]. Oncogene, 2021, 40:6007-6022.
[10]	Fan L, Xu C, Ge Q, et al. A. Muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-Mediated M1-like TAMs[J]. Cancer Immunol Res, 2021, 9:1111-1124.
[11]	Xu J, Guo R, Jia J, et al. Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8(+) T cell cytotoxicity in patients with gastric cancer[J]. BMC Immunol, 2021, 22:67.doi:10.1186/s12865-021-00459-z.
[12]	Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation[J]. J Immunol, 2005, 175:8242-8252.
[13]	Zhu G, Cheng Z, Huang Y, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF-κB/AP-1 signaling pathway[J]. Int J Mol Med, 2020, 45:131-140.
[14]	Xu Z, Lv Z, Chen F, et al. Dysbiosis of human tumor microbiome and aberrant residence of actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer[J]. Front Immunol, 2022, 13:1008975.doi:10.3389/fimmu.2022.1008975.
[15]	Liu YD, Ji CB, Li SB, et al. Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-κB signaling pathways[J]. Int Immunopharmacol, 2018, 59:375-383.
[16]	Chen X, Zhang L, Jiang Y, et al. Radiotherapy-induced cell death activates paracrine HMGB1-TLR2 signaling and accelerates pancreatic carcinoma metastasis[J]. J Exp Clin Cancer Res, 2018, 37:77.doi:10.1186/s13046-018-0726-2.
[17]	Kajino-Sakamoto R, Fujishita T, Taketo MM, et al. Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells[J]. Oncogene, 2021, 40:408-420.
[18]	Tang F, Cao F, Lu C, et al. Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression[J]. Cancer Sci, 2022, 113:565-575.
[19]	Zhang S, Wang J, Chen T, et al. α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the Akt/GSK3β/β-Catenin pathway[J]. Bioengineered, 2021, 12:5688-5704.
[20]	Gao L, Wang TH, Chen CP, et al. Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma[J]. Transl Cancer Res, 2021, 10:2219-2228.
[21]	Ma J, Zhang C, Liang W, et al. ω-3 and ω-6 polyunsaturated fatty acids regulate the proliferation, invasion and angiogenesis of gastric cancer through COX/PGE signaling pathway[J]. Front Oncol, 2022, 12:802009.doi:10.3389/fonc.2022.802009.
[22]	Wu L, Sun J, Liu L, et al. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways[J]. Int Immunopharmacol, 2020, 82:106368.doi:10.1016/j.intimp.2020.106368.
[23]	Khedr OMS, El-Sonbaty SM, Moawed FSM, et al. Lactobacillus acidophilus ATCC 4356 exopolysaccharides suppresses mediators of inflammation through the inhibition of TLR2/STAT-3/P38-MAPK pathway in DEN-induced hepatocarcinogenesis in rats[J]. Nutr Cancer, 2022, 74:1037-1047.
[24]	Xie X, Lv H, Liu C, et al. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis[J]. BMC Med, 2021, 19:247.doi:10.1186/s12916-021-02085-3.
[25]	Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice[J]. Gastroenterology, 2017, 152:1419-1433.
[26]	Li S, Li F, Xu L, et al. TLR2 agonist promotes myeloid-derived suppressor cell polarization via Runx1 in hepatocellular carcinoma[J]. Int Immunopharmacol, 2022, 111:109168.doi:10.1016/j.intimp.2022.109168.
[27]	Bermudez M, Grabowski M, Murgueitio MS, et al. Biological characterization, mechanistic investigation and structure-activity relationships of chemically stable TLR2 antagonists[J]. Chem Med Chem, 2020, 15:1364-1371.